GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (OTCPK:RSLS) » Definitions » Cyclically Adjusted Revenue per Share

Reshape Lifesciences (Reshape Lifesciences) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Reshape Lifesciences Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Reshape Lifesciences's adjusted revenue per share for the three months ended in Dec. 2023 was $0.566. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Reshape Lifesciences's average Cyclically Adjusted Revenue Growth Rate was -8.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Reshape Lifesciences was 396.20% per year. The lowest was -6.90% per year. And the median was 106.95% per year.

As of today (2024-04-28), Reshape Lifesciences's current stock price is $2.76. Reshape Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.00. Reshape Lifesciences's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Reshape Lifesciences was 0.24. The lowest was 0.01. And the median was 0.04.


Reshape Lifesciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Reshape Lifesciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Cyclically Adjusted Revenue per Share Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Reshape Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reshape Lifesciences's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Reshape Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Cyclically Adjusted PS Ratio falls into.



Reshape Lifesciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Reshape Lifesciences's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.566/129.4194*129.4194
=0.566

Current CPI (Dec. 2023) = 129.4194.

Reshape Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.016 100.684 0.021
201509 0.009 100.392 0.012
201512 0.021 99.792 0.027
201603 0.643 100.470 0.828
201606 1.878 101.688 2.390
201609 0.536 101.861 0.681
201612 0.256 101.863 0.325
201703 0.007 102.862 0.009
201706 0.186 103.349 0.233
201709 0.567 104.136 0.705
201712 0.120 104.011 0.149
201803 9.267 105.290 11.391
201806 0.556 106.317 0.677
201809 0.031 106.507 0.038
201812 6.164 105.998 7.526
201903 44.551 107.251 53.760
201906 41.981 108.070 50.275
201909 13.019 108.329 15.554
201912 10.332 108.420 12.333
202003 0.407 108.902 0.484
202006 0.246 108.767 0.293
202009 0.517 109.815 0.609
202012 0.460 109.897 0.542
202103 0.462 111.754 0.535
202106 0.572 114.631 0.646
202109 1.059 115.734 1.184
202112 0.898 117.630 0.988
202203 0.697 121.301 0.744
202206 0.826 125.017 0.855
202209 0.799 125.227 0.826
202212 0.889 125.222 0.919
202303 0.653 127.348 0.664
202306 0.644 128.729 0.647
202309 0.616 129.860 0.614
202312 0.566 129.419 0.566

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Reshape Lifesciences  (OTCPK:RSLS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Reshape Lifesciences was 0.24. The lowest was 0.01. And the median was 0.04.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Reshape Lifesciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (Reshape Lifesciences) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Barton P. Bandy officer: President and CEO 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Dan W Gladney director, officer: Chairman, President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Scott P Youngstrom officer: CFO and SVP, Finance 2800 PATTON ROAD ST. PAUL MN 55113
Joseph Patrick Healey 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
Healthcor Partners Ii, L.p. 10 percent owner 152 W. 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Michael Y Mashaal director 309 WAVERLEY OAKS RD., SUITE 105 WALTHAM MA 02452
Healthcor Partners Fund Ii, L.p. 10 percent owner CARNEGIE HILL TOWER 152 WEST 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Jeffrey C Lightcap 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019
Healthcor Partners Management Gp, Llc 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019

Reshape Lifesciences (Reshape Lifesciences) Headlines

From GuruFocus